Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4
Journal Title: Annals of Hepatology - Year 2013, Vol 12, Issue 1
Abstract
The hepatitis C virus (HCV) genotype is an important predictive outcome parameter for pegylated interferonplus ribavirin therapy. Most published therapeutic trials to date have enrolled mainly patients with HCV genotypes 1, 2 and 3. Limited studies have focused on genotype 4 patients, who have had a poor representation in pivotal trials. Our aim was to evaluate the efficacy and safety of treatment with standard dose pegylated interferon alfa-2a in combination with weight-based ribavirin in patients with chronic hepatitis C genotype 4. In this prospective observational study, 198 patients with HCV-4 were included in this study from February 2004 to August 2005,188 patients who received at least 1 dose of drugs were included in the ITT analysis and they were treated with pegylated interferon alfa-2a and ribavirin for 48 weeks. Baseline and demographic characteristics, response to treatment at weeks 12, 48 and 72, and the nature and frequency of adverse effects were analyzed. Virological response at week 12 was achieved in 144 patients (76.6%). Virological response at the end of treatment was present in 110 patients (58.5%). At week 72, 99 patients presented SVR (52.7%). The reported adverse events were similar to those found in the literature for treatments of similar dose and duration. In conclusion, combined treatment with pegylated interferon alfa-2a and ribavirin was well tolerated and effective in chronic hepatitis C genotype 4, yielding response rates between those reported for genotype 1 and those of genotypes 2-3.
Authors and Affiliations
Juan Urquijo, Moisés Diago, Jaume Boadas, Ramón Planas, Ricard Solá, Javier Crespo, José Erdozaín, María Antón, Carlos Arocena, Dolores Suarez, Josep Giné, Ricardo Perez, Blai Dalmau, Miguel Montoro
Keywords
Related Articles
- EP ID EP78228
- DOI -
- Views 95
- Downloads 0
Review of the neurological manifestations of hepatitis E infection
Hepatitis E (HEV) is a common infection worldwide and is an emerging disease in developed countries. The presence of extra-hepatic manifestation of HEV infection is important to bear in mind so that the diagnosis is not...
Therapeutic effects of granulocyte-colony stimulating factor on non-alcoholic hepatic steatosis in the rat
[b]Background and rationale[/b]. Non-alcoholic hepatic steatosis refers to the accumulation of triglycerides in the liver in the absence of alcohol consumption. Granulocyte colony-stimulating factor (G-CSF) has been repo...
Hepatic Hydrothorax
Hepatic hydrothorax (HH) is a pleural effusion that develops in a patient with cirrhosis and portal hypertension in the absence of cardiopulmonary disease. Although the development of HH remains incompletely understood,...
Drug-induced liver injury in hospitalized HIV patients: high incidence and association with drugs for tuberculosis
Background. The evaluation of liver disease in HIV patients is cumbersome because may result from a number of different causes. The aim of this retrospective study was to estimate the incidence of severe drug induced liv...
Potential Molecular Targets of Statins in the Prevention of Hepatocarcinogenesis
Hepatocellular carcinoma (HCC) represents 90% of liver tumors. Statins, may reduce the incidence of various tumors, including HCC. Antitumoral activities may be mediated by changes in transforming growth factor-beta (TGF...